Comparative Expression of ER,PR and HER2/Neu in Initial and Recurrent Breast Cancer.

Expression of ER, PR and HER2/neu in initial and recurrent breast cancer and correlate the results to different clinical and pathological parameters as patient age,sex, tumor location, status of nodal involvement and lymphovascular invasion

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Breast Cancer Breast Diseases Breast Neoplasms Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Sex eligibility

Female

Study type

Observational

Primary location

Faculty of medicine

Sohag, Egypt

About this study

Clinical data, pathological data, expression status of ER, PR and HER2/neu of both initial tumor and recurrent tumor and received treatment for BC patients diagnosed between January 2021 and December 2024 will be extracted from archive of multidisciplinary team (MDT) for management of BC at Sohag Oncology Center. In addition; hematoxylin and eosin stained slides and immune-stained slides for ER, PR and HER2/neu for selected patient's will be retrieved from archives of Pathology unit at Sohag Oncology Center and reviewed to confirm pathological features, ER expression, PR expression and HER2 status of both initial and recurrent tumor tissues.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with excised breast cancer then experienced recurrence at same site. Patients with evaluated ER, PR and HER2/neu for both initial and recurrent tumors.

Exclusion criteria

Cases with insufficient clinical of pathological data. Deficient ER, PR and HER2/neu status in either initial or recurrent tumor

Treatment and study plan

Primary outcomes

Comparison between initial and recurrent breast cancer in immunohistochemical expression of ER,PR and HER2/neu

Time frame: 6 months

Secondary outcomes

Correlate the results of immunohistochemical expression of ER,PRand HER2/neu with the patients age ,sex,nodal status and lymphovascular invasion

Time frame: 6 months

Sponsors and collaborators

Lead sponsor

Sohag University

Other

Registry information

Important dates

Study start: 2021
Primary completion: 2025
Study completion: 2025
First posted: Jul 9, 2025
Registry last updated: Jul 9, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Enrolling by Invitation